GlobeNewsWire
14 Jun 2026, 18:45 UTC · 14w ago
Verdict
Headline takes no side. We score CRNX +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Long-term data from PATHFNDR-1 and PATHFNDR-2 trials show PALSONIFY maintains durable IGF-1 control and stable symptoms for up to two years.
More positive than 93% of claims this week
PALSONIFY demonstrated the ability to maintain or reduce pituitary tumor volumes in patients for up to 48 weeks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
Combination therapy of PALSONIFY and cabergoline showed improved biochemical control in the ACROBAT Advance study.
More positive than 66% of claims this week
The drug was well-tolerated with no new safety signals identified in the pooled open-label extension population.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company presented positive long-term clinical data showing that PALSONIFY provides durable and consistent control of acromegaly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
16h ago
+146.4%
Price agrees with the score
$84.95 vs $34.47 close before publication (Jun 12) · not market-adjusted
CRNX chart →
